Lorundrostat hydrobromide is under clinical development by Mineralys Therapeutics and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lorundrostat hydrobromide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lorundrostat hydrobromide overview
Mineralys Therapeutics overview
Mineralys Therapeutics. (Mineralys Therapeutics) is a private, clinical-stage biopharmaceutical company that develops novel therapy for the treatment of hypertension. Mineralys Therapeutics is headquartered in Radnor, Pennsylvania, the US.
For a complete picture of Lorundrostat hydrobromide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.